Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-07-30 Capital/Financing Update
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AstraZeneca prices a €1.4bn bond offering
Capital/Financing Update Classification · 98% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) from AstraZeneca PLC. The content explicitly details the successful pricing of a €1.4 billion Eurobond offering by its subsidiary, including coupon rates, maturity dates, and the intended use of proceeds. This activity falls directly under financing and capital structure changes. Based on the provided definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification for an announcement regarding the issuance of debt instruments (Eurobonds). Although it is distributed via RNS, the specific nature of the content (bond pricing) overrides the general 'RNS' fallback.
2024-07-30 English
CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed clinical trial results and scientific data about the AMPLIFY Phase III trial for Calquence in chronic lymphocytic leukemia. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about clinical trial outcomes and company developments. The length of the document (11,929 characters) and the detailed content indicate it is not a brief announcement or a report publication announcement. The Form 6-K is a standard SEC filing for foreign issuers to report material information. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-07-29 English
Calquence fixed-duration combo improved 1L CLL PFS
Earnings Release Classification · 99% confidence The document begins with 'RNS Number : 1029Y' and is dated '29 July 2024'. It details positive high-level results from a Phase III clinical trial (AMPLIFY) for a drug (Calquence) and includes commentary from company executives and investigators. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief announcement of significant news (clinical trial results) distributed via the RNS system—is characteristic of a general regulatory announcement that doesn't fit the specific financial report categories (like 10-K, IR, ER). Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement fallback. Q3 2024
2024-07-29 English
ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the FDA Oncologic Drugs Advisory Committee (ODAC) review of Imfinzi for resectable lung cancer, including clinical trial results, regulatory status, and company commentary. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a drug development and regulatory review process. Form 6-K filings are typically classified as Regulatory Filings (RNS) in the classification scheme provided, as they are miscellaneous regulatory announcements from foreign issuers that do not fit into other specific categories.
2024-07-26 English
ODAC reviewed Imfinzi in resectable lung cancer
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from AstraZeneca PLC, dated July 26, 2024. It details the outcome of an FDA Oncologic Drugs Advisory Committee (ODAC) review regarding the drug Imfinzi for resectable non-small cell lung cancer (NSCLC), based on the AEGEAN Phase III trial results. This is a specific, time-sensitive update concerning regulatory interaction and clinical trial data, rather than a comprehensive annual report (10-K), a quarterly report (IR), or a formal earnings release (ER). Since it is a general regulatory announcement that doesn't fit the more specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Management Discussion (MDA), the most appropriate classification is the general regulatory filing category, RNS, which serves as a broad category for such announcements.
2024-07-26 English
FORM 6K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting H1 and Q2 2024 financial results. It includes detailed financial data such as revenue, EPS, margins, and guidance updates. The document contains substantive financial performance information for a half-year period, including actual financial statements and analysis. It is not merely an announcement or a certification but a comprehensive interim financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-07-25 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.